No Detail Found!

Clinical eficacy and safety of targeted therapy, immunotherapy combined with chemotherapy for treating patients with advanced gastric cancer

Author(s)
Dongyan Yang Department of Oncology Three Ward, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, China.
Zhilong Gao Department of Gastrointestinal Medicine III, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, China.
Xuezhu Yang Department of Gastroendoscopy, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, China.
Liguo Gao Department of Oncology Three Ward, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, China.
Abstract
Objective: Exploring the clinical eficacy and safety of targeted therapy, immunotherapy combined with chemotherapy in the treatment of advanced gastric cancer. Methods: A retrospective analysis was performed on the medical records of 134 patients with advanced gastric cancer who visited Renmin Hospital, Hubei University of Medicine from January 2019 to December 2022. According to therapeutic regimens, enrolled patients were divided into the control group and the study group. Patients in the control group received chemotherapy intervention, while those in the study group were provided with a combined intervention of apatinib, PD-1 inhibitor and chemotherapy. We analyze the tumor control efect and incidence of adverse reactions in two groups of patients. Results: The disease control rate (DCR) of patients in the study group and the control group was 72.06% and 42.42%, with an overall response rate (ORR) of 8.82% and 4.55%, The diferences are statistically significant(P0.05). Conclusion: The therapeutic regimen of apatinib, a PD-1 inhibitor combined with chemotherapy exhibits relatively high clinical eficacy and safety for the treatment of patients with advanced gastric cancer. It can be considered as an interventional option for this type of patient.
Publication Details
Page(s) 2101-2106
Published Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 9, Year: 2024

Request the full text from PASTIC

Keywords
chemotherapy, apatinib, Advanced gastric cancer, PD-1 inhibitor
References
Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I,Jemal A,Cancer J Clin A .2021 .GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Global Cancer Statistics, 10(3) : 209-249.
Zheng RS,Zhang SW,Zeng HM,Wang S,Sun K,Chenet R,Nat Cancer Center J .2022 .Cancer incidence and. , 02(1) : 1-9.
Chen Y,Chen Y,Wang Z,Li H,Wang Y. .2022 .Clinical value of propranolol combined with oxaliplatin and tigio in concurrent chemoradiotherapy for locally advanced gastric cancer. Pak J Med Sci, 10(5) : 5311-1320.
Li WW,Jiao J,Wang ZY,Wei YN,Zhang YF. .2021 .Clinical efficacy of immunotherapy combined with chemotherapy in patients with advanced gastric cancer, its effect on nutritional status and Changes of peripheral blood T lymphocyte subsets. Pak J Med Sci, 10(7) : 4347-1907.
Bouzid R,Peppelenbosch M,Buschow SI .2020 .Opportunities for Conventional and in Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. Cancers (Basel), 10(5) : 1121.
Janjigian YY,Kawazoe A,Bai Y,Xu J,Lonardi S,Metges JP .2023 .Pembrolizumab plus trastuzumab and chemotherapy for HER2- positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet, 6736(23) : 02033-0.
Shitara K,Ajani JA,Moehler M,Garrido M,Gallardo C,Shen L .2022 .Nivolumab plus chemotherapy or ipilimumab in gastrooesophageal cancer. Nature, 10(7903) : 942-948.
Kwon HJ,Park MI,Park SJ,Moon W,Kim SE,Kim JH .2019 .Insulin Resistance Is Associated with Early Gastric Cancer: A Prospective Multicenter Case Control Study. Gut Liver, 10(2) : 154-160.
Shitara K,Bang YJ,Iwasa S,Sugimoto N,Ryu MH,Sakai D .2020 .Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med, 10(25) : 2419-2430.
Zhou N,Zhang C,Liu D,Liu K,Wang G,Zhu H .2021 .Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial. , 10(3) : e374-e381.
Wei J,Lu X,Liu Q,Li L,Liu S,Liu F .2020 .. Case Report: Neoadjuvant PD-1 Blockade Plus Concurrent Chemoradiotherapy in Unresectable Locally Advanced Gastric Cancer Patients. Front Oncol, 10 : 554040.
Zhang Y,Wang F,Sun HR,Huang YK,Gao JP,Huang H .2021 .Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer. J Cancer Res Clin Oncol, 10(8) : 2209-2222.
Zhang L,Wang W,Ge S,Li H,Bai M,Duan J .2023 .Sintilimab Plus Apatinib and Chemotherapy as Second/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial. BMC Cancer, 10(1) : 211.
Roviello G,Ravelli A,Polom K,Petrioli R,Marano L,Marrelli D .2016 .Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett, 01(2) : 187-191.
Luo Q,Dong Z,Xie W,Fu X,Lin L,Zeng Q .2023 .Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy. Cell Rep, 10(5) : 112437.
Lin R,Fan N,Li H,Liu J,Zhao S,Yu J .2020 .Apatinib reverses resistance of paclitaxel-containing regimens in advanced gastric cancer: A phase II study. , 10(Suppl 9) : ix53-ix54.
Zheng Y,Yang X,Yan C,Feng R,Sah BK,Yang Z .2020 .Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial. Eur J Cancer, 02 : 12-19.
Wang Y,Zhao J,Yu H,Wang J,Zhang N,Cao B .2021 .Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma. J Cancer Res Ther, 856(5) : 21-1240.
Jiang H,Yu X,Li N,Kong M,Zhou Z,D Z .2022 .Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. -003635, 10(3) : .
0

Citations

0

Downloads

64

Views